Diffusion and Characterization of Pseudomonas aeruginosa Aminoglycoside Resistance in an Italian Regional Cystic Fibrosis Centre.
Acquired resistance determinants
Aminoglycoside resistance
Cystic fibrosis
Efflux pumps
Pseudomonas aeruginosa
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
13
7
2020
medline:
15
4
2021
entrez:
13
7
2020
Statut:
ppublish
Résumé
Extensively-drug-resistant Pseudomonas aeruginosa constitutes a serious threat to patients suffering from Cystic Fibrosis (CF). In these patients, P. aeruginosa lung infection is commonly treated with aminoglycosides, but treatments are largely unsuccessful due a variety of resistance mechanisms. Here we investigate the prevalence of resistance to gentamicin, amikacin and tobramycin and the main aminoglycoside resistance genes found in P. aeruginosa strains isolated at a regional CF centre. A total number of 147 randomly selected P. aeruginosa strains isolated from respiratory samples sent by the Marche regional Cystic Fibrosis Centre to the Microbiology lab, were included in this study. Of these, 78 (53%) were resistant to at least one of the three aminoglycosides tested and 27% were resistant to all three antibiotics, suggesting a major involvement of a chromosome-encoded mechanism, likely MexXY-OprM efflux pump overexpression. A specific pathogenic clone (found in 7/78 of the aminoglycoside resistant strains) carrying ant(2″)-Ia was isolated over time from the same patient, suggesting a role for this additional resistance gene in the antibiotic unresponsiveness of CF patients. The MexXY-OprM efflux pump is confirmed as the resistance determinant involved most frequently in P. aeruginosa aminoglycoside resistance of CF lung infections, followed by the ant(2″)-Ia-encoded adenylyltransferase. The latter may prove to be a novel target for new antimicrobial combinations against P. aeruginosa.
Identifiants
pubmed: 32654097
doi: 10.1007/5584_2020_570
doi:
Substances chimiques
Aminoglycosides
0
Anti-Bacterial Agents
0
Bacterial Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-80Références
Aron Z, Opperman TJ (2016) Optimization of a novel series of pyranopyridine RND efflux pump inhibitors. Curr Opin Microbiol 33:1–6
doi: 10.1016/j.mib.2016.05.007
Beaudoin T, Zhang L, Hinz AJ et al (2012) The biofilm-specific antibiotic resistance gene ndvB is important for expression of ethanol oxidation genes in Pseudomonas aeruginosa biofilms. J Bacteriol 194:3128–3136
doi: 10.1128/JB.06178-11
Biavasco F, Foglia C, Paoletti G et al (2007) VanA-type enterococci from humans, animals, and food: species distribution, population structure, Tn1546 typing and location, and virulence determinants. Appl Environ Microbiol 73:307–3319
doi: 10.1128/AEM.02239-06
Bolard A, Plésiat P, Jeannot K (2018) Mutations in gene fusA1 as a novel mechanism of aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 62:e01835–e01817
pubmed: 29133559
pmcid: 5786765
Buttini F, Balducci AG, Colombo G et al (2018) Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. Int J Pharm 548:182–191
doi: 10.1016/j.ijpharm.2018.06.006
Colque CA, Albarracín Orio AG, Feliziani S et al (2020) Hypermutator Pseudomonas aeruginosa exploits multiple genetic pathways to develop multidrug resistance during long-term infections in the airways of cystic fibrosis patients. Antimicrob Agents Chemother 64:e02142-19
doi: 10.1128/AAC.02142-19
Costello SE, Deshpande LM, Davis AP et al (2018) Aminoglycoside-modifying enzymes and 16S ribosomal RNA methyltransferases-encoding genes among a global collection of gram-negative isolates. J Glob Antimicrob Resist 16:278–285
doi: 10.1016/j.jgar.2018.10.020
European Committee for Antimicrobial Susceptibility Testing (EUCAST) (2003) Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. EUCAST discussion document E. Dis 5.1. Clin Microbiol Infect 9:1–7
European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. EUCAST, Basel. Accessed 2016
Frimodt-Møller J, Rossi E, Haagensen JAJ et al (2018) Mutations causing low level antibiotic resistance ensure bacterial survival in antibiotic-treated hosts. Sci Rep 8:12512
doi: 10.1038/s41598-018-30972-y
Hall CW, Hinz AJ, Gagnon LB et al (2018) Pseudomonas aeruginosa biofilm antibiotic resistance gene ndvB expression requires the RpoS stationary-phase sigma factor. Appl Environ Microbiol 84:e02762–e02717
doi: 10.1128/AEM.02762-17
Hynes WL, Ferretti JJ, Gilmore MS et al (1992) PCR amplification of streptococcal DNA using crude cell lysates. FEMS Microbiol Lett 73:139–142
doi: 10.1111/j.1574-6968.1992.tb05303.x
Kiddee A, Henghiranyawong K, Yimsabai J et al (2013) Nosocomial spread of class 1 integron-carrying extensively drug-resistant Pseudomonas aeruginosa isolates in a Thai hospital. Int J Antimicrob Agents 42:301–306
doi: 10.1016/j.ijantimicag.2013.05.009
Lamers RP, Cavallari JF, Burrows LL (2013) The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One 8:e60666
doi: 10.1371/journal.pone.0060666
Laudadio E, Cedraro N, Mangiaterra G et al (2019) Natural alkaloid Berberine activity against Pseudomonas aeruginosa MexXY-mediated aminoglycoside resistance: In Silico and in Vitro studies. J Nat Prod 82:1935–1944
doi: 10.1021/acs.jnatprod.9b00317
López-Causapé C, Cabot G, Del Barrio-Tofiño E et al (2018) The versatile mutational Resistome of Pseudomonas aeruginosa. Front Microbiol 9:685
doi: 10.3389/fmicb.2018.00685
Mah TF, Pitts B, Pellock B et al (2003) A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306–310
doi: 10.1038/nature02122
Mangiaterra G, Laudadio E, Cometti M et al (2017) Inhibitors of multidrug efflux pumps of Pseudomonas aeruginosa from natural sources: an in silico high-throughput virtual screening and in vitro validation. Med Chem Res 26:414–430
doi: 10.1007/s00044-016-1761-1
Martin LW, Robson CL, Watts AM (2018) Expression of Pseudomonas aeruginosa antibiotic resistance genes varies greatly during infections in cystic fibrosis patients. Antimicrob Agents Chemother 62:e01789–e01718
doi: 10.1128/AAC.01789-18
Michalska AD, Sacha PT, Ojdana D et al (2014) Prevalence of resistance to aminoglycosides and fluoroquinolones among Pseudomonas aeruginosa strains in a University Hospital in Northeastern Poland. Braz J Microbiol 45:1455–1458
doi: 10.1590/S1517-83822014000400041
Morita Y, Tomida J, Kawamura Y (2012) MexXY multidrug efflux system of Pseudomonas aeruginosa. Front Microbiol 3:408
doi: 10.3389/fmicb.2012.00408
Mostofian F, Alkadri J, Tang K et al (2019) A real world evaluation of the long-term efficacy of strategies to prevent chronic Pseudomonas Aeruginosa pulmonary infection in children with cystic fibrosis. Int J Infect Dis 85:92–97
doi: 10.1016/j.ijid.2019.05.026
Mózes J, Szűcs I, Molnár D et al (2014) A potential role of aminoglycoside resistance in endemic occurrence of Pseudomonas Aeruginosa strains in lower airways of mechanically ventilated patients. Diagn Microbiol Infect Dis 78:79–84
doi: 10.1016/j.diagmicrobio.2013.09.015
Müller L, Murgia X, Siebenbürger L et al (2018) Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin. J Antimicrob Chemother 73:2762–2769
doi: 10.1093/jac/dky241
Mustafa MH, Chalhoub H, Denis O et al (2016) Antimicrobial susceptibility of Pseudomonas Aeruginosa isolated from cystic fibrosis patients in northern Europe. Antimicrob Agents Chemother 60:6735–6741
doi: 10.1128/AAC.01046-16
Oh H, Stenhoff J, Jalal S et al (2003) Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Resist 9:323–328
doi: 10.1089/107662903322762743
Partridge SR, Kwong SM, Firth N et al (2018) Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev 31:e00088–e00017
doi: 10.1128/CMR.00088-17
Poole K (2005) Aminoglycoside Resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:479–487
doi: 10.1128/AAC.49.2.479-487.2005
Poole K (2011) Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2:65
doi: 10.3389/fmicb.2011.00065
Prickett MH, Hauser AR, McColley SA et al (2017) Aminoglycoside resistance of Pseudomonas Aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene. Thorax 72:40–47
doi: 10.1136/thoraxjnl-2015-208027
Qin X, Zhou C, Zerr DM et al (2018) Heterogeneous antimicrobial susceptibility characteristics in Pseudomonas aeruginosa isolates from cystic fibrosis patients. mSphere 3:e00615–e00617
doi: 10.1128/mSphere.00615-17
Ramirez MS, Tolmasky ME (2010) Aminoglycoside modifying enzymes. Drug Resist Updat 13:151–171
doi: 10.1016/j.drup.2010.08.003
Ratjen F, Moeller A, McKinney ML et al (2019) Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: the early study. J Cyst Fibros 18:78–85
doi: 10.1016/j.jcf.2018.04.002
Seifert H, Dolzani L, Bressan R et al (2005) Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 43:4328–4335
doi: 10.1128/JCM.43.9.4328-4335.2005
Smith WD, Bardin E, Cameron L et al (2017) Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS Microbiol Lett 364(14):1–9
doi: 10.1093/femsle/fnx121
Soto SM (2013) Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence 4:223–229
doi: 10.4161/viru.23724
Stanojevic S, Waters V, Mathew JL et al (2014) Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. J Cyst Fibros 13:172–178
doi: 10.1016/j.jcf.2013.09.002
Woegerbauer M, Zeinzinger J, Springer B et al (2004) Prevalence of the aminoglycoside phosphotransferase genes aph(3′)-IIIa and aph(3′)-IIa in Escherichia coli, Enterococcus faecalis, Enterococcus faecium, Pseudomonas aeruginosa, Salmonella enterica subsp. enterica and Staphylococcus aureus isolates in Austria. J Med Microbiol 63:210–217
doi: 10.1099/jmm.0.065789-0
Yamane K, Doi Y, Yokoyama K et al (2004) Genetic environments of the rmtA gene in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 48:2069–2074
doi: 10.1128/AAC.48.6.2069-2074.2004